Chronic Graft-Versus-Host Disease (GVHD) in children

Pediatric Clinics of North America

Volumn 57, Issue 1, 2010, Pages 297-322

  Baird, Kristin ^a   Cooke, Kenneth ^b,c   Schultz, Kirk R ^d,e  

^a NATIONAL CANCER INSTITUTE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e BC CHILDREN S HOSPITAL   (Canada)

Author keywords

Children; Chronic graft versus host disease; GVHD; Hematopoeitic stem cell transplant

Indexed keywords

ALEMTUZUMAB; ANTIFUNGAL AGENT; ANTIPRURITIC AGENT; ANTIVIRUS AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCINEURIN INHIBITOR; CALCIUM; CLOTRIMAZOLE; CORTICOSTEROID; CYCLOSPORIN; CYCLOSPORIN A; DACLIZUMAB; DERMATOLOGICAL AGENT; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; METHOTREXATE; METHOXSALEN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NYSTATIN; PENTOSTATIN; PREDNISONE; RAPAMYCIN; RITUXIMAB; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; UNINDEXED DRUG; VITAMIN D;

ACUTE GRAFT VERSUS HOST DISEASE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AUTOIMMUNE DISEASE; BONE DENSITY; CANCER MORTALITY; CANDIDIASIS; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; CORD BLOOD STEM CELL TRANSPLANTATION; CYTOPENIA; DIAGNOSTIC TEST; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESPONSE; ENGRAFTMENT; EYE DISEASE; GASTROINTESTINAL DISEASE; HAIR DISEASE; HEMATOLOGIC DISEASE; HEMOLYTIC UREMIC SYNDROME; HISTOPATHOLOGY; HLA MATCHING; HUMAN; HYPERLIPIDEMIA; IMMUNOGLOBULIN DEFICIENCY; IMMUNOPATHOLOGY; INCIDENCE; INFECTION; LUNG DISEASE; MALIGNANT NEOPLASTIC DISEASE; MOUTH DISEASE; MUSCULOSKELETAL DISEASE; NAIL DISEASE; OCCUPATIONAL THERAPY; PATHOPHYSIOLOGY; PHOTOCHEMOTHERAPY; PHYSIOTHERAPY; PRURITUS; QUALITY OF LIFE; REVIEW; RISK FACTOR; SIDE EFFECT; SKIN DISEASE; SKIN MANIFESTATION; SPLINTING; SURVIVAL RATE; SURVIVAL TIME; TREATMENT RESPONSE; VIRUS INFECTION; VULVOVAGINAL DISEASE;

CHILD; CHRONIC DISEASE; GLUCOCORTICOIDS; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; PROGNOSIS; SURVIVAL RATE; TRANSPLANTATION, HOMOLOGOUS;

EID: 77951084356     PISSN: 00313955     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pcl.2009.11.003     Document Type: Review

References (190)

1. Pasquini M., Wang Z., Schneider L. Current use and outcome of hematopoietic stem cell transplantation: part I - CIBMTR summary slides, 2007. CIBMTR Newsletter 2007, 13:5-9.
2. Notarangelo L.D., Forino C., Mazzolari E. Stem cell transplantation in primary immunodeficiencies. Curr Opin Allergy Clin Immunol 2006, 6:443-448.
3. Walters M.C. Stem cell therapy for sickle cell disease: transplantation and gene therapy. Hematology Am Soc Hematol Educ Program 2005, 66-73.
4. Walters M.C., Quirolo L., Trachtenberg E.T., et al. Sibling donor cord blood transplantation for thalassemia major: experience of the Sibling Donor Cord Blood Program. Ann N Y Acad Sci 2005, 1054:206-213.
5. Gaziev J., Lucarelli G. Stem cell transplantation for thalassaemia. Reprod Biomed Online 2005, 10:111-115.
6. Kennedy-Nasser A.A., Leung K.S., Mahajan A., et al. Comparable outcomes of matched-related and alternative donor stem cell transplantation for pediatric severe aplastic anemia. Biol Blood Marrow Transplant 2006, 12:1277-1284.
7. Peters C., Steward C.G. Hematopoietic cell transplantation for inherited metabolic diseases: an overview of outcomes and practice guidelines. Bone Marrow Transplant 2003, 31:229-239.
8. Atkinson K. Chronic graft-versus-host disease. Bone Marrow Transplant 1990, 5:69-82.
9. Deeg H.J., Leisenring W., Storb R., et al. Long-term outcome after marrow transplantation for severe aplastic anemia. Blood 1998, 91:3637-3645.
10. Gilman A.L., Chan K.W., Mogul A., et al. Hydroxychloroquine for the treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2000, 6:327-334.
11. Lee S.J., Klein J.P., Barrett A.J., et al. Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. Blood 2002, 100:406-414.
12. Goerner M., Gooley T., Flowers M.E., et al. Morbidity and mortality of chronic GVHD after hematopoietic stem cell transplantation from HLA-identical siblings for patients with aplastic or refractory anemias. Biol Blood Marrow Transplant 2002, 8:47-56.
13. Storb R., Prentice R.L., Sullivan K.M., et al. Predictive factors in chronic graft-versus-host disease in patients with aplastic anemia treated by marrow transplantation from HLA-identical siblings. Ann Intern Med 1983, 98:461-466.
14. Atkinson K., Horowitz M.M., Gale R.P., et al. Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation. Blood 1990, 75:2459-2464.
15. Sullivan K.M., Shulman H.M., Storb R., et al. Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. Blood 1981, 57:267-276.
16. Ochs L.A., Miller W.J., Filipovich A.H., et al. Predictive factors for chronic graft-versus-host disease after histocompatible sibling donor bone marrow transplantation. Bone Marrow Transplant 1994, 13:455-460.
17. Eapen M., Horowitz M.M., Klein J.P., et al. Higher mortality after allogeneic peripheral-blood transplantation compared with bone marrow in children and adolescents: the Histocompatibility and Alternate Stem Cell Source Working Committee of the International Bone Marrow Transplant Registry. J Clin Oncol 2004, 22:4872-4880.
18. Higman M.A., Vogelsang G.B. Chronic graft versus host disease. Br J Haematol 2004, 125:435-454.
19. Zecca M., Prete A., Rondelli R., et al. Chronic graft-versus-host disease in children: incidence, risk factors, and impact on outcome. Blood 2002, 100:1192-1200.
20. Busca A., Rendine S., Locatelli F., et al. Chronic graft-versus-host disease after reduced-intensity stem cell transplantation versus conventional hematopoietic stem cell transplantation. Hematology 2005, 10:1-10.
21. Lee S.J., Vogelsang G., Flowers M.E. Chronic graft-versus-host disease. Biol Blood Marrow Transplant 2003, 9:215-233.
22. Akpek G., Lee S.J., Flowers M.E., et al. Performance of a new clinical grading system for chronic graft-versus-host disease: a multicenter study. Blood 2003, 102:802-809.
23. Shulman H.M., Sullivan K.M., Weiden P.L., et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980, 69:204-217.
24. Filipovich A.H., Weisdorf D., Pavletic S., et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005, 11:945-956.
25. Wagner J.E., Kernan N.A., Steinbuch M., et al. Allogeneic sibling umbilical-cord-blood transplantation in children with malignant and non-malignant disease. Lancet 1995, 346:214-219.
26. Meisel R., Laws H.J., Balzer S., et al. Comparable long-term survival after bone marrow versus peripheral blood progenitor cell transplantation from matched unrelated donors in children with hematologic malignancies. Biol Blood Marrow Transplant 2007, 13:1338-1345.
27. Rocha V., Wagner J.E., Sobocinski K.A., et al. Graft-versus-host disease in children who have received a cord-blood or bone marrow transplant from an HLA-identical sibling. Eurocord and International Bone Marrow Transplant Registry Working Committee on Alternative Donor and Stem Cell Sources. N Engl J Med 2000, 342:1846-1854.
28. van Els C.A., Bakker A., Zwinderman A.H., et al. Effector mechanisms in graft-versus-host disease in response to minor histocompatibility antigens. II. Evidence of a possible involvement of proliferative T cells. Transplantation 1990, 50:67-71.
29. de Bueger M., Bakker A., Bontkes H., et al. High frequencies of cytotoxic T cell precursors against minor histocompatibility antigens after HLA-identical BMT: absence of correlation with GVHD. Bone Marrow Transplant 1993, 11:363-368.
30. Mutis T., Gillespie G., Schrama E., et al. Tetrameric HLA class I-minor histocompatibility antigen peptide complexes demonstrate minor histocompatibility antigen-specific cytotoxic T lymphocytes in patients with graft-versus-host disease. Nat Med 1999, 5:839-842.
31. Zhang C., Todorov I., Zhang Z., et al. Donor CD4+ T and B cells in transplants induce chronic graft-versus-host disease with autoimmune manifestations. Blood 2006, 107:2993-3001.
32. Rouquette-Gally A.M., Boyeldieu D., Prost A.C., et al. Autoimmunity after allogeneic bone marrow transplantation. A study of 53 long-term-surviving patients. Transplantation 1988, 46:238-240.
33. Quaranta S., Shulman H., Ahmed A., et al. Autoantibodies in human chronic graft-versus-host disease after hematopoietic cell transplantation. Clin Immunol 1999, 91:106-116.
34. Allan S.E., Crome S.Q., Crellin N.K., et al. Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production. Int Immunol 2007, 19:345-354.
35. Schultz K.R., Paquet J., Bader S., et al. Requirement for B cells in T cell priming to minor histocompatibility antigens and development of graft-versus-host disease. Bone Marrow Transplant 1995, 16:289-295.
36. Miklos D.B., Kim H.T., Zorn E., et al. Antibody response to DBY minor histocompatibility antigen is induced after allogeneic stem cell transplantation and in healthy female donors. Blood 2004, 103:353-359.
37. Miklos D.B., Kim H.T., Miller K.H., et al. Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. Blood 2005, 105:2973-2978.
38. Brink R. Regulation of B cell self-tolerance by BAFF. Semin Immunol 2006, 18:276-283.
39. Wechalekar A., Cranfield T., Sinclair D., et al. Occurrence of autoantibodies in chronic graft vs. host disease after allogeneic stem cell transplantation. Clin Lab Haematol 2005, 27:247-249.
40. Graze P.R., Gale R.P. Chronic graft versus host disease: a syndrome of disordered immunity. Am J Med 1979, 66:611-620.
41. Vogelsang G.B. How I treat chronic graft-versus-host disease. Blood 2001, 97:1196-1201.
42. Svegliati S., Olivieri A., Campelli N., et al. Stimulatory autoantibodies to PDGF receptor in patients with extensive chronic graft-versus-host disease. Blood 2007, 110:237-241.
43. Baroni S.S., Santillo M., Bevilacqua F., et al. Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med 2006, 354:2667-2676.
44. Ferrara J.L., Deeg H.J. Graft-versus-host disease. N Engl J Med 1991, 324:667-674.
45. Kollman C., Howe C.W., Anasetti C., et al. Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. Blood 2001, 98:2043-2051.
46. Randolph S.S., Gooley T.A., Warren E.H., et al. Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched, related hematopoietic stem cell transplants. Blood 2004, 103:347-352.
47. Cutler C., Miklos D., Kim H.T., et al. Rituximab for steroid-refractory chronic graft-vs.-host disease. Blood 2006, 108(2):756-762.
48. New J.Y., Li B., Koh W.P., et al. T cell infiltration and chemokine expression: relevance to the disease localization in murine graft-versus-host disease. Bone Marrow Transplant 2002, 29:979-986.
49. Hildebrandt G.C., Duffner U.A., Olkiewicz K.M., et al. A critical role for CCR2/MCP-1 interactions in the development of idiopathic pneumonia syndrome after allogeneic bone marrow transplantation. Blood 2004, 103:2417-2426.
50. Imamura M., Hashino S., Kobayashi H., et al. Serum cytokine levels in bone marrow transplantation: synergistic interaction of interleukin-6, interferon-gamma, and tumor necrosis factor-alpha in graft-versus-host disease. Bone Marrow Transplant 1994, 13:745-751.
51. Okamoto H., Yamamura M., Morita Y., et al. The synovial expression and serum levels of interleukin-6, interleukin-11, leukemia inhibitory factor, and oncostatin M in rheumatoid arthritis. Arthritis Rheum 1997, 40:1096-1105.
52. Banovic T., MacDonald K.P., Morris E.S., et al. TGF-beta in allogeneic stem cell transplantation: friend or foe?. Blood 2005, 106:2206-2214.
53. Theofilopoulos A.N., Baccala R., Beutler B., et al. Type I interferons (alpha/beta) in immunity and autoimmunity. Annu Rev Immunol 2005, 23:307-336.
54. Foley R., Couban S., Walker I., et al. Monitoring soluble interleukin-2 receptor levels in related and unrelated donor allogenic bone marrow transplantation. Bone Marrow Transplant 1998, 21:769-773.
55. Grimm J., Zeller W., Zander A.R. Soluble interleukin-2 receptor serum levels after allogeneic bone marrow transplantations as a marker for GVHD. Bone Marrow Transplant 1998, 21:29-32.
56. Miyamoto T., Akashi K., Hayashi S., et al. Serum concentration of the soluble interleukin-2 receptor for monitoring acute graft-versus-host disease. Bone Marrow Transplant 1996, 17:185-190.
57. Kobayashi S., Imamura M., Hashino S., et al. Clinical relevance of serum soluble interleukin-2 receptor levels in acute and chronic graft-versus-host disease. Leuk Lymphoma 1997, 28:159-169.
58. Liu J., Anderson B.E., Robert M.E., et al. Selective T-cell subset ablation demonstrates a role for T1 and T2 cells in ongoing acute graft-versus-host disease: a model system for the reversal of disease. Blood 2001, 98:3367-3375.
59. Campen D.H., Horwitz D.A., Quismorio F.P., et al. Serum levels of interleukin-2 receptor and activity of rheumatic diseases characterized by immune system activation. Arthritis Rheum 1988, 31:1358-1364.
60. Hayashi T., Morishita E., Ontachi Y., et al. Effects of sarpogrelate hydrochloride in a patient with chronic graft-versus-host disease: a case report. Am J Hematol 2006, 81:121-123.
61. Chang D.M., Wang C.J., Kuo S.Y., et al. Cell surface markers and circulating cytokines in graft versus host disease. Immunol Invest 1999, 28:77-86.
62. Via C.S., Rus V., Gately M.K., et al. IL-12 stimulates the development of acute graft-versus-host disease in mice that normally would develop chronic, autoimmune graft-versus-host disease. J Immunol 1994, 153:4040-4047.
63. Cavet J., Dickinson A.M., Norden J., et al. Interferon-gamma and interleukin-6 gene polymorphisms associate with graft-versus-host disease in HLA-matched sibling bone marrow transplantation. Blood 2001, 98:1594-1600.
64. Stark G.L., Dickinson A.M., Jackson G.H., et al. Tumour necrosis factor receptor type II 196M/R genotype correlates with circulating soluble receptor levels in normal subjects and with graft-versus-host disease after sibling allogeneic bone marrow transplantation. Transplantation 2003, 76:1742-1749.
65. Rocha V., Franco R.F., Porcher R., et al. Host defense and inflammatory gene polymorphisms are associated with outcomes after HLA-identical sibling bone marrow transplantation. Blood 2002, 100:3908-3918.
66. Lin M.T., Storer B., Martin P.J., et al. Relation of an interleukin-10 promoter polymorphism to graft-versus-host disease and survival after hematopoietic-cell transplantation. N Engl J Med 2003, 349:2201-2210.
67. She K., Gilman A.L., Aslanian S., et al. Altered Toll-like receptor 9 responses in circulating B cells at the onset of extensive chronic graft-versus-host disease. Biol Blood Marrow Transplant 2007, 13:386-397.
68. Fujii H., Cuvelier G., She K., et al. Biomarkers in newly diagnosed pediatric extensive chronic graft-versus-host disease: a report from the Children's Oncology Group. Blood 2008, 111(6):3276-3285.
69. Saarinen-Pihkala U.M., Gustafsson G., Ringden O., et al. No disadvantage in outcome of using matched unrelated donors as compared with matched sibling donors for bone marrow transplantation in children with acute lymphoblastic leukemia in second remission. J Clin Oncol 2001, 19:3406-3414.
70. Barge R.M., Osanto S., Marijt W.A., et al. Minimal GVHD following in-vitro T cell-depleted allogeneic stem cell transplantation with reduced-intensity conditioning allowing subsequent infusions of donor lymphocytes in patients with hematological malignancies and solid tumors. Exp Hematol 2003, 31:865-872.
71. Langrish C.L., Buddle J.C., Thrasher A.J., et al. Neonatal dendritic cells are intrinsically biased against Th-1 immune responses. Clin Exp Immunol 2002, 128:118-123.
72. Tasker L., Marshall-Clarke S. Functional responses of human neonatal B lymphocytes to antigen receptor cross-linking and CpG DNA. Clin Exp Immunol 2003, 134:409-419.
73. Oakhill A., Pamphilon D.H., Potter M.N., et al. Unrelated donor bone marrow transplantation for children with relapsed acute lymphoblastic leukaemia in second complete remission. Br J Haematol 1996, 94:574-578.
74. Fleming D.R., Henslee-Downey P.J., Romond E.H., et al. Allogeneic bone marrow transplantation with T cell-depleted partially matched related donors for advanced acute lymphoblastic leukemia in children and adults: a comparative matched cohort study. Bone Marrow Transplant 1996, 17:917-922.
75. Bunin N., Saunders F., Leahey A., et al. Alternative donor bone marrow transplantation for children with juvenile myelomonocytic leukemia. J Pediatr Hematol Oncol 1999, 21:479-485.
76. Green A., Clarke E., Hunt L., et al. Children with acute lymphoblastic leukemia who receive T-cell-depleted HLA mismatched marrow allografts from unrelated donors have an increased incidence of primary graft failure but a similar overall transplant outcome. Blood 1999, 94:2236-2246.
77. Pavletic S.Z., Carter S.L., Kernan N.A., et al. Influence of T-cell depletion on chronic graft-versus-host disease: results of a multicenter randomized trial in unrelated marrow donor transplantation. Blood 2005, 106:3308-3313.
78. Baron F., Maris M.B., Storer B.E., et al. High doses of transplanted CD34+ cells are associated with rapid T-cell engraftment and lessened risk of graft rejection, but not more graft-versus-host disease after nonmyeloablative conditioning and unrelated hematopoietic cell transplantation. Leukemia 2005, 19:822-828.
79. Burroughs L., Mielcarek M., Leisenring W., et al. Extending postgrafting cyclosporine decreases the risk of severe graft-versus-host disease after nonmyeloablative hematopoietic cell transplantation. Transplantation 2006, 81:818-825.
80. Wall D.A., Carter S.L., Kernan N.A., et al. Busulfan/melphalan/antithymocyte globulin followed by unrelated donor cord blood transplantation for treatment of infant leukemia and leukemia in young children: the Cord Blood Transplantation study (COBLT) experience. Biol Blood Marrow Transplant 2005, 11:637-646.
81. Bacigalupo A., Lamparelli T., Barisione G., et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biol Blood Marrow Transplant 2006, 12:560-565.
82. Chakrabarti S., MacDonald D., Hale G., et al. T-cell depletion with Campath-1H " in the bag" for matched related allogeneic peripheral blood stem cell transplantation is associated with reduced graft-versus-host disease, rapid immune constitution and improved survival. Br J Haematol 2003, 121:109-118.
83. Duval M., Pedron B., Rohrlich P., et al. Immune reconstitution after haematopoietic transplantation with two different doses of pre-graft antithymocyte globulin. Bone Marrow Transplant 2002, 30:421-426.
84. Mohty M. Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond. Leukemia 2007, 21:1387-1394.
85. Giralt S. The role of alemtuzumab in nonmyeloablative hematopoietic transplantation. Semin Oncol 2006, 33:S36-S43.
86. Balduzzi A., Gooley T., Anasetti C., et al. Unrelated donor marrow transplantation in children. Blood 1995, 86:3247-3256.
87. Davies S.M., Wagner J.E., Defor T., et al. Unrelated donor bone marrow transplantation for children and adolescents with aplastic anaemia or myelodysplasia. Br J Haematol 1997, 96:749-756.
88. Bunin N., Carston M., Wall D., et al. Unrelated marrow transplantation for children with acute lymphoblastic leukemia in second remission. Blood 2002, 99:3151-3157.
89. Talano J.A., Margolis D.A. Recent molecular and cellular advances in pediatric bone marrow transplantation. Pediatr Clin North Am 2006, 53:685-698.
90. Woolfrey A.E., Anasetti C., Storer B., et al. Factors associated with outcome after unrelated marrow transplantation for treatment of acute lymphoblastic leukemia in children. Blood 2002, 99:2002-2008.
91. Giebel S., Giorgiani G., Martinetti M., et al. Low incidence of severe acute graft-versus-host disease in children given haematopoietic stem cell transplantation from unrelated donors prospectively matched for HLA class I and II alleles with high-resolution molecular typing. Bone Marrow Transplant 2003, 31:987-993.
92. Grupp S.A., Frangoul H., Wall D., et al. Use of G-CSF in matched sibling donor pediatric allogeneic transplantation: a consensus statement from the Children's Oncology Group (COG) Transplant Discipline Committee and Pediatric Blood and Marrow Transplant Consortium (PBMTC) Executive Committee. Pediatr Blood Cancer 2006, 46:414-421.
93. Cutler C., Antin J.H. Peripheral blood stem cells for allogeneic transplantation: a review. Stem Cells 2001, 19:108-117.
94. Flowers M.E., Parker P.M., Johnston L.J., et al. Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial. Blood 2002, 100:415-419.
95. Champlin R.E., Schmitz N., Horowitz M.M., et al. Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. IBMTR Histocompatibility and Stem Cell Sources Working Committee and the European Group for Blood and Marrow Transplantation (EBMT). Blood 2000, 95:3702-3709.
96. Watanabe T., Kajiume T., Abe T., et al. Allogeneic peripheral blood stem cell transplantation in children with hematologic malignancies from HLA-matched siblings. Med Pediatr Oncol 2000, 34:171-176.
97. Benito A.I., Gonzalez-Vicent M., Garcia F., et al. Allogeneic peripheral blood stem cell transplantation (PBSCT) from HLA-identical sibling donors in children with hematological diseases: a single center pilot study. Bone Marrow Transplant 2001, 28:537-543.
98. Diaz M.A., Gonzalez-Vicent M., Gonzalez M.E., et al. Long-term outcome of allogeneic PBSC transplantation in pediatric patients with hematological malignancies: a report of the Spanish Working Party for Blood and Marrow Transplantation in Children (GETMON) and the Spanish Group for Allogeneic Peripheral Blood Transplantation (GETH). Bone Marrow Transplant 2005, 36:781-785.
99. Rubinstein P., Carrier C., Scaradavou A., et al. Outcomes among 562 recipients of placental-blood transplants from unrelated donors. N Engl J Med 1998, 339:1565-1577.
100. Thomson B.G., Robertson K.A., Gowan D., et al. Analysis of engraftment, graft-versus-host disease, and immune recovery following unrelated donor cord blood transplantation. Blood 2000, 96:2703-2711.
101. Yu L.C., Wall D.A., Sandler E., et al. Unrelated cord blood transplant experience by the pediatric blood and marrow transplant consortium. Pediatr Hematol Oncol 2001, 18:235-245.
102. Gluckman E., Rocha V., Chevret S. Results of unrelated umbilical cord blood hematopoietic stem cell transplantation. Rev Clin Exp Hematol 2001, 5:87-99.
103. Wagner J.E., Barker J.N., DeFor T.E., et al. Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood 2002, 100:1611-1618.
104. Barker J.N. Who should get cord blood transplants? Biol Blood Marrow Transplant 2007, 13(Suppl 1):78-82.
105. Eapen M., Rubinstein P., Zhang M.J., et al. Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study. Lancet 2007, 369:1947-1954.
106. Kamani N., Spellman S., Hurley C.K., et al. State of the art review: HLA matching and outcome of unrelated donor umbilical cord blood transplants. Biol Blood Marrow Transplant 2008, 14:1-6.
107. Arora M., Nagaraj S., Wagner J.E., et al. Chronic graft-versus-host disease (cGVHD) following unrelated donor hematopoietic stem cell transplantation (HSCT): higher response rate in recipients of unrelated donor (URD) umbilical cord blood (UCB). Biol Blood Marrow Transplant 2007, 13:1145-1152.
108. Akpek G., Zahurak M.L., Piantadosi S., et al. Development of a prognostic model for grading chronic graft-versus-host disease. Blood 2001, 97:1219-1226.
109. Lee S., Cook E.F., Soiffer R., et al. Development and validation of a scale to measure symptoms of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2002, 8:444-452.
110. Imai H., Oyama Y., Miura A.B., et al. Hematopoietic cell transplantation-related nephropathy in Japan. Am J Kidney Dis 2000, 36:474-480.
111. Srinivasan R., Balow J.E., Sabnis S., et al. Nephrotic syndrome: an under-recognised immune-mediated complication of non-myeloablative allogeneic haematopoietic cell transplantation. Br J Haematol 2005, 131:74-79.
112. Colombo A.A., Rusconi C., Esposito C., et al. Nephrotic syndrome after allogeneic hematopoietic stem cell transplantation as a late complication of chronic graft-versus-host disease. Transplantation 2006, 81:1087-1092.
113. Gilman A.L., Kooy N.W., Atkins D.L., et al. Complete heart block in association with graft-versus-host disease. Bone Marrow Transplant 1998, 21:85-88.
114. Rackley C., Schultz K.R., Goldman F.D., et al. Cardiac manifestations of graft-versus-host disease. Biol Blood Marrow Transplant 2005, 11:773-780.
115. Couriel D., Carpenter P.A., Cutler C., et al. Ancillary therapy and supportive care of chronic graft-versus-host disease: national institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: V. Ancillary Therapy and Supportive Care Working Group Report. Biol Blood Marrow Transplant 2006, 12:375-396.
116. Chosidow O., Bagot M., Vernant J.P., et al. Sclerodermatous chronic graft-versus-host disease. Analysis of seven cases. J Am Acad Dermatol 1992, 26:49-55.
117. Penas P.F., Jones-Caballero M., Aragues M., et al. Sclerodermatous graft-vs-host disease: clinical and pathological study of 17 patients. Arch Dermatol 2002, 138:924-934.
118. Beredjiklian P.K., Drummond D.S., Dormans J.P., et al. Orthopaedic manifestations of chronic graft-versus-host disease. J Pediatr Orthop 1998, 18:572-575.
119. Stern J.M., Chesnut C.H., Bruemmer B., et al. Bone density loss during treatment of chronic GVHD. Bone Marrow Transplant 1996, 17:395-400.
120. Tauchmanova L., De Rosa G., Serio B., et al. Avascular necrosis in long-term survivors after allogeneic or autologous stem cell transplantation: a single center experience and a review. Cancer 2003, 97:2453-2461.
121. Franklin R.M., Kenyon K.R., Tutschka P.J., et al. Ocular manifestations of graft-vs-host disease. Ophthalmology 1983, 90:4-13.
122. Pavletic S.Z., Martin P., Lee S.J., et al. Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group Report. Biol Blood Marrow Transplant 2006, 12:252-266.
123. Treister N.S., Woo S.B., O'Holleran E.W., et al. Oral chronic graft-versus-host disease in pediatric patients after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005, 11:721-731.
124. Imanguli M.M., Pavletic S.Z., Guadagnini J.P., et al. Chronic graft versus host disease of oral mucosa: review of available therapies. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006, 101:175-183.
125. Jacobsohn D.A., Montross S., Anders V., et al. Clinical importance of confirming or excluding the diagnosis of chronic graft-versus-host disease. Bone Marrow Transplant 2001, 28:1047-1051.
126. Browning B., Thormann K., Seshadri R., et al. Weight loss and reduced body mass index: a critical issue in children with multiorgan chronic graft-versus-host disease. Bone Marrow Transplant 2006, 37:527-533.
127. Shulman H.M., Sharma P., Amos D., et al. A coded histologic study of hepatic graft-versus-host disease after human bone marrow transplantation. Hepatology 1988, 8:463-470.
128. Strasser S.I., Shulman H.M., Flowers M.E., et al. Chronic graft-versus-host disease of the liver: presentation as an acute hepatitis. Hepatology 2000, 32:1265-1271.
129. Akpek G., Boitnott J.K., Lee L.A., et al. Hepatitic variant of graft-versus-host disease after donor lymphocyte infusion. Blood 2002, 100:3903-3907.
130. Melin-Aldana H., Thormann K., Duerst R., et al. Hepatitic pattern of graft versus host disease in children. Pediatr Blood Cancer 2007, 49:727-730.
131. Cooke K.R., Yanik G. Lung injury following hematopoietic cell transplantation. Thomas' hematopoietic cell transplantation 2009, Wiley-Blackwell. 4th edition. F.R. Appelbaum, S.J. Forman, R.S. Negrin (Eds.).
132. Afessa B., Litzow M.R., Tefferi A. Bronchiolitis obliterans and other late onset non-infectious pulmonary complications in hematopoietic stem cell transplantation. Bone Marrow Transplant 2001, 28:425-434.
133. Dudek A.Z., Mahaseth H., DeFor T.E., et al. Bronchiolitis obliterans in chronic graft-versus-host disease: analysis of risk factors and treatment outcomes. Biol Blood Marrow Transplant 2003, 9:657-666.
134. Ratanatharathorn V., Ayash L., Lazarus H.M., et al. Chronic graft-versus-host disease: clinical manifestation and therapy. Bone Marrow Transplant 2001, 28:121-129.
135. Freudenberger T.D., Madtes D.K., Curtis J.R., et al. Association between acute and chronic graft-versus-host disease and bronchiolitis obliterans organizing pneumonia in recipients of hematopoietic stem cell transplants. Blood 2003, 102:3822-3828.
136. Yoshihara S., Yanik G., Cooke K.R., et al. Bronchiolitis obliterans syndrome (BOS), bronchiolitis obliterans organizing pneumonia (BOOP), and other late-onset noninfectious pulmonary complications following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2007, 13:749-759.
137. Khouri I.F., Ippoliti C., Gajewski J., et al. Neutropenias following allogeneic bone marrow transplantation: response to therapy with high-dose intravenous immunoglobulin. Am J Hematol 1996, 52:313-315.
138. Au W.Y., Lo C.M., Hawkins B.R., et al. Evans' syndrome complicating chronic graft versus host disease after cadaveric liver transplantation. Transplantation 2001, 72:527-528.
139. Tomonari A., Tojo A., Lseki T., et al. Severe autoimmune thrombocytopenia after allogeneic bone marrow transplantation for aplastic anemia. Int J Hematol 2001, 74:228-232.
140. Sullivan K.M., Witherspoon R.P., Storb R., et al. Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation. Blood 1988, 72:546-554.
141. Nevo S., Enger C., Hartley E., et al. Acute bleeding and thrombocytopenia after bone marrow transplantation. Bone Marrow Transplant 2001, 27:65-72.
142. Jacobsohn D.A., Schechter T., Seshadri R., et al. Eosinophilia correlates with the presence or development of chronic graft-versus-host disease in children. Transplantation 2004, 77:1096-1100.
143. Siadak M., Sullivan K.M. The management of chronic graft-versus-host disease. Blood Rev 1994, 8:154-160.
144. Storek J., Witherspoon R.P., Webb D., et al. Lack of B cells precursors in marrow transplant recipients with chronic graft-versus-host disease. Am J Hematol 1996, 52:82-89.
145. Maury S., Mary J.Y., Rabian C., et al. Prolonged immune deficiency following allogeneic stem cell transplantation: risk factors and complications in adult patients. Br J Haematol 2001, 115:630-641.
146. Atkinson K. Reconstruction of the haemopoietic and immune systems after marrow transplantation. Bone Marrow Transplant 1990, 5:209-226.
147. Storek J., Witherspoon R.P., Maloney D.G., et al. Improved reconstitution of CD4 T cells and B cells but worsened reconstitution of serum IgG levels after allogeneic transplantation of blood stem cells instead of marrow. Blood 1997, 89:3891-3893.
148. Rege K., Mehta J., Treleaven J., et al. Fatal pneumococcal infections following allogeneic bone marrow transplant. Bone Marrow Transplant 1994, 14:903-906.
149. Kulkarni S., Powles R., Treleaven J., et al. Chronic graft versus host disease is associated with long-term risk for pneumococcal infections in recipients of bone marrow transplants. Blood 2000, 95:3683-3686.
150. Stewart B.L., Storer B., Storek J., et al. Duration of immunosuppressive treatment for chronic graft-versus-host disease. Blood 2004, 104:3501-3506.
151. Martin P.J., Storer B.E., Rowley S.D., et al. Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease. Blood 2009, 113:5074-5082.
152. Wingard J.R., Piantadosi S., Vogelsang G.B., et al. Predictors of death from chronic graft-versus-host disease after bone marrow transplantation. Blood 1989, 74:1428-1435.
153. Sehgal S.N. Rapamune (Sirolimus, rapamycin): an overview and mechanism of action. Ther Drug Monit 1995, 17:660-665.
154. Benito A.I., Furlong T., Martin P.J., et al. Sirolimus (rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease. Transplantation 2001, 72:1924-1929.
155. Cutler C., Antin J.H. Sirolimus for GVHD prophylaxis in allogeneic stem cell transplantation. Bone Marrow Transplant 2004, 34:471-476.
156. Couriel D.R., Saliba R., Escalon M.P., et al. Sirolimus in combination with tacrolimus and corticosteroids for the treatment of resistant chronic graft-versus-host disease. Br J Haematol 2005, 130:409-417.
157. Johnston L.J., Brown J., Shizuru J.A., et al. Rapamycin (sirolimus) for treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2005, 11:47-55.
158. Jurado M., Vallejo C., Perez-Simon J.A., et al. Sirolimus as part of immunosuppressive therapy for refractory chronic graft-versus-host disease. Biol Blood Marrow Transplant 2007, 13:701-706.
159. Mookerjee B., Altomonte V., Vogelsang G. Salvage therapy for refractory chronic graft-versus-host disease with mycophenolate mofetil and tacrolimus. Bone Marrow Transplant 1999, 24:517-520.
160. Busca A., Saroglia E.M., Lanino E., et al. Mycophenolate mofetil (MMF) as therapy for refractory chronic GVHD (cGVHD) in children receiving bone marrow transplantation. Bone Marrow Transplant 2000, 25:1067-1071.
161. Yusuf U.S.J., Stephan V. Mycophenolate mofetil (MMF) as salvage treatment for steroid-refractory chronic graft-versus-host-disease (GVHD) in children. Blood 2001, 98:398a. [abstract].
162. Lopez F., Parker P., Nademanee A., et al. Efficacy of mycophenolate mofetil in the treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2005, 11:307-313.
163. Krejci M., Doubek M., Buchler T., et al. Mycophenolate mofetil for the treatment of acute and chronic steroid-refractory graft-versus-host disease. Ann Hematol 2005, 84:681-685.
164. Giblett E.R., Anderson J.E., Cohen F., et al. Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity. Lancet 1972, 2:1067-1069.
165. Saven A., Piro L. Newer purine analogues for the treatment of hairy-cell leukemia. N Engl J Med 1994, 330:691-697.
166. Jacobsohn D.A., Chen A.R., Zahurak M., et al. Phase II study of pentostatin in patients with corticosteroid-refractory chronic graft-versus-host disease. J Clin Oncol 2007, 25:4255-4261.
167. Mackenzie A.H. Antimalarial drugs for rheumatoid arthritis. Am J Med 1983, 75:48-58.
168. Olson N.Y., Lindsley C.B. Adjunctive use of hydroxychloroquine in childhood dermatomyositis. J Rheumatol 1989, 16:1545-1547.
169. Vogelsang G.B., Farmer E.R., Hess A.D., et al. Thalidomide for the treatment of chronic graft-versus-host disease. N Engl J Med 1992, 326:1055-1058.
170. Cole C.H., Rogers P.C., Pritchard S., et al. Thalidomide in the management of chronic graft-versus-host disease in children following bone marrow transplantation. Bone Marrow Transplant 1994, 14:937-942.
171. Rovelli A., Arrigo C., Nesi F., et al. The role of thalidomide in the treatment of refractory chronic graft-versus-host disease following bone marrow transplantation in children. Bone Marrow Transplant 1998, 21:577-581.
172. Edelson R., Berger C., Gasparro F., et al. Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary results. N Engl J Med 1987, 316:297-303.
173. Greinix H.T., Volc-Platzer B., Kalhs P., et al. Extracorporeal photochemotherapy in the treatment of severe steroid-refractory acute graft-versus-host disease: a pilot study. Blood 2000, 96:2426-2431.
174. Couriel D., Hosing C., Saliba R., et al. Extracorporeal photopheresis for acute and chronic graft-versus-host disease: does it work?. Biol Blood Marrow Transplant 2006, 12:37-40.
175. Couriel D.R., Hosing C., Saliba R., et al. Extracorporeal photochemotherapy for the treatment of steroid-resistant chronic GVHD. Blood 2006, 107:3074-3080.
176. Foss F.M., DiVenuti G.M., Chin K., et al. Prospective study of extracorporeal photopheresis in steroid-refractory or steroid-resistant extensive chronic graft-versus-host disease: analysis of response and survival incorporating prognostic factors. Bone Marrow Transplant 2005, 35:1187-1193.
177. Rubegni P., Cuccia A., Sbano P., et al. Role of extracorporeal photochemotherapy in patients with refractory chronic graft-versus-host disease. Br J Haematol 2005, 130:271-275.
178. Salvaneschi L., Perotti C., Zecca M., et al. Extracorporeal photochemotherapy for treatment of acute and chronic GVHD in childhood. Transfusion 2001, 41:1299-1305.
179. Messina C., Locatelli F., Lanino E., et al. Extracorporeal photochemotherapy for paediatric patients with graft-versus-host disease after haematopoietic stem cell transplantation. Br J Haematol 2003, 122:118-127.
180. Srinivasan R., Chakrabarti S., Walsh T., et al. Improved survival in steroid-refractory acute graft versus host disease after non-myeloablative allogeneic transplantation using a daclizumab-based strategy with comprehensive infection prophylaxis. Br J Haematol 2004, 124:777-786.
181. Yanik G.A., Uberti J.P., Ferrara J.L.M., et al. Etanercept for sub-acute lung injury following allogeneic stem cell transplantation. Blood 2003, 102:471a.
182. Busca A., Locatelli F., Marmont F., et al. Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation. Am J Hematol 2007, 82:45-52.
183. Magro L., Mohty M., Catteau B., et al. Imatinib mesylate as salvage therapy for refractory sclerotic chronic graft-versus-host disease. Blood 2009, 114:719-722.
184. Olivieri A., Locatelli F., Zecca M., et al. Imatinib for refractory chronic graft-versus-host disease with fibrotic features. Blood 2009, 114:709-718.
185. Leung W., Ahn H., Rose S.R., et al. A prospective cohort study of late sequelae of pediatric allogeneic hematopoietic stem cell transplantation. Medicine (Baltimore) 2007, 86:215-224.
186. Falcini F., Taccetti G., Trapani S., et al. Growth retardation in juvenile chronic arthritis patients treated with steroids. Clin Exp Rheumatol 1991, 9(Suppl 6):37-40.
187. Lai H.C., FitzSimmons S.C., Allen D.B., et al. Risk of persistent growth impairment after alternate-day prednisone treatment in children with cystic fibrosis. N Engl J Med 2000, 342:851-859.
188. Baker K.S., Fraser C.J. Quality of life and recovery after graft-versus-host disease. Best Pract Res Clin Haematol 2008, 21:333-341.
189. Lee S.J., Kim H.T., Ho V.T., et al. Quality of life associated with acute and chronic graft-versus-host disease. Bone Marrow Transplant 2006, 38:305-310.
190. Oeffinger K.C., Mertens A.C., Sklar C.A., et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 2006, 355:1572-1582.